Q1 2026 Halozyme Therapeutics Inc Earnings Call Transcript
Key Points
- Halozyme Therapeutics Inc (HALO) reported a 42% year-over-year increase in total revenue for the first quarter of 2026, reaching $377 million.
- The company's royalty revenues increased by 43% year-over-year to $241 million, driven by the strong performance of ENHANZE-enabled products.
- Halozyme Therapeutics Inc (HALO) reaffirmed its full-year 2026 financial guidance, projecting ENHANZE royalties to exceed $1 billion for the first time.
- The company announced a new $1 billion share buyback authorization, with plans to repurchase at least $400 million of shares in 2026.
- Halozyme Therapeutics Inc (HALO) has signed three new collaboration and licensing agreements in 2026, expanding its ENHANZE and Hypercon partnerships.
- Research and development expenses increased to $25.6 million from $14.8 million in the prior year period, reflecting integration costs for Hypercon and Surf Bio acquisitions.
- Selling, general, and administrative expenses rose to $57.9 million compared to $42.4 million in the prior year period.
- The company faces challenges in identifying drug delivery M&A opportunities that meet its high criteria, with no transactions expected in 2026.
- The launch timing for Hypercon products is projected for 2030-2031, indicating a longer wait for revenue realization from these products.
- The company is still in the early stages of realizing the full potential of its enhanced royalties, indicating that significant growth may take time to materialize.
Good afternoon. My name is Melissa, and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's first-quarter 2026 financial and operating results conference call. Please note, this event is being recorded.
I will now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations and Corporate Communications. Please go ahead.
Thank you, operator. Good afternoon, and welcome to our first quarter 2026 financial and operating results conference call. In addition to the press release issued today after the market closed you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.
Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Dave Ramsay, our Interim Chief Financial Officer, will review our financial results as well as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
